<DOC>
	<DOCNO>NCT00355342</DOCNO>
	<brief_summary>This study last 3 year . You visit clinic 14 time . Certain visit include lung function test scan bone . The purpose study determine effect steroid component inhale product bone mineral density patient Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease . DISKUSÂ® Inhaler Trademark GSK Group Companies .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Established clinical history COPD . Baseline FEV1 &lt; 70 % predict normal , FEV1/FVC ratio le 70 % . Smoking history least 10 packyears , current former smoker eligible . Must least one native , evaluable hip . Exclusion criterion : History evidence metabolic bone diseases osteoporosis osteopenia .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
</DOC>